Why is the A2 Milk share price spilling 8% today?

It's been a tough day for A2 Milk shareholders.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • A2 Milk shares plummet by more than 7% during midday trade 
  • Investors are reacting to the surprise announcement that the company's FDA application has been deferred 
  • Two brokers, however, believe that A2 Milk shares are attractively valued 

The A2 Milk Company Ltd (ASX: A2M) share price is having a day to forget on Wednesday.

This comes after the embattled company provided an update regarding its FDA application to import products into the United States.

During the first few minutes of market open, shares in the infant formula company dropped to an intraday low of $4.60.

However, since then, its shares have moved in circles to currently trade at $4.71, down 7.83%.

a small girl sits with her hand holding up the side of her face as she looks down in a downcast manner as she drinks a glass of milk through a straw.

Image source: Getty Images

Why did the A2 Milk share price fall?

The notice from the US Food and Drug Administration (FDA) to defer further requests to import infant milk formula (IMF) products into the United States is impacting the A2 Milk share price today.

The shock news appears to have caught investors off guard after A2 Milk shares rose more than 10% in the past week.

This followed the recent media speculation that the company was nearing FDA approval, in which management dismissed the report thereafter.

Nonetheless, A2 Milk would have been hoping to receive a similar outcome to its smaller rival, Bubs Australia Ltd (ASX: BUB). The latter secured a deal with the Biden Administration to import 1.25 million tins of baby formula into the United States.

An article from The Australian reported that Wilsons analyst James Ferrier said the FDA decision "could suggest US authorities are becoming more comfortable with the supply situation."

Earlier this year, US consumers faced an infant formula shortage following potential contamination at one of its largest manufacturing plants.

Ferrier also went on to add:

This is obviously a disappointing outcome for A2 Milk in regards to short-term earnings potential or an opportunity to build brand awareness in the US.

It also creates uncertainty for those who have secured temporary market access, in relation to prospects for more permanent market access beyond November, which is the end date of the policy.

It is worth noting though that while the update may leave a sour taste in investors' mouths, the revenue outlook remains the same.

Management is expecting to achieve revenue growth this year after reporting a 2.5% decline to $661 million in H1 FY22.

A2 Milk is scheduled to report its full year results on Tuesday 30 August.

Is the A2 Milk share price a buy despite its latest woes?

Despite the setback, a couple of brokers believe that the A2 Milk share price is currently trading at a bargain price.

Wilsons has a market weight rating and a $5.98 price target on the company's shares. Based on the current price, this implies an upside of around 27%.

Furthermore, Morgans believes A2 Milk shares are worth $6.39 apiece according to its last valuation.

While more bullish than Wilsons' price target, this implies an upside of 35% for investors.

Motley Fool contributor Aaron Teboneras has positions in A2 Milk. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended A2 Milk and BUBS AUST FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Consumer Staples & Discretionary Shares

Two happy shoppers looking at a smartphone together.
Share Market News

Why did ASX 200 retail shares outperform last week?

Wesfarmers, Light & Wonder, Nick Scali, and Temple & Webster shares surged 10% or more.

Read more »

Excited couple celebrating success while looking at smartphone.
Consumer Staples & Discretionary Shares

Guess which ASX 200 stock is avoiding the selloff and charging higher on big news

What is driving this stock higher? Let's find out.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Consumer Staples & Discretionary Shares

Down 52% in 2026, why this ASX All Ords stock now looks 'incredibly cheap'

A leading fund manager is buying the dip on this beaten down ASX All Ords stock. But why?

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

3 compelling reasons to buy the rebound in Coles shares today

A leading analyst expects the rebound in Coles shares could have much further to run.

Read more »

A man in a business suit holds his hand up to his mouth as though sharing a secret and gives a sly grin.
Consumer Staples & Discretionary Shares

Why this ASX 200 stock is climbing after a $2 million insider buy

A buyback update and insider buying have investors watching closely.

Read more »

A woman smiles as she stands next to a car loaded with a stack of suitcases on the roof.
Consumer Staples & Discretionary Shares

Bell Potter just tipped 12% to 34% upside for these consumer discretionary stocks

These shares could be a value play.

Read more »

Man holding Australian dollar notes, symbolising dividends.
Consumer Staples & Discretionary Shares

Here's the dividend forecast out to 2028 for Coles shares

The supermarket business is on course to give investors great dividend income.

Read more »

A happy couple drinking red wine in a vineyard.
Consumer Staples & Discretionary Shares

Treasury Wine shares jump 12% on big investor update

Investors are saying cheers to the Penfolds owner's plans.

Read more »